Has Robert Doebele received payments from drug or device companies?

Yes. Drug and device makers reported $38,282 in general payments to Robert Doebele across 58 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robert Doebele did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robert Doebele come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robert Doebele

Medical Oncology · Aurora, CONPI 1952424830

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 36.3% of the total.

$38,282in general payments, 2019–2025

Across 58 payments — averaging $660.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

F. Hoffmann-la Roche AG$14K
Genentech USA, Inc.$6K
Takeda Pharmaceuticals U.S.A., Inc.$5K
Foundation Medicine, Inc.$4K
Boehringer Ingelheim International GmbH$4K
Hoffmann-la Roche Limited$3K
plus $2K from 4 others

$1,280,595in research payments, 2019–2025

Across 115 payments — averaging $11,136 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Blueprint Medicines Corporation$521K
Genentech, Inc.$471K
Pfizer$238K
AstraZeneca$18K
F. Hoffmann-la Roche AG$17K
Astrazeneca UK Limited$17K

What the payments were for

Consulting fees$18,90549%
Speaking & faculty fees$17,90347%
Travel & lodging$4851%
Food & beverage$9903%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
F. Hoffmann-la Roche AG	30	$13,903
Genentech USA, Inc.	4	$6,331
Takeda Pharmaceuticals U.S.A., Inc.	6	$4,531
Foundation Medicine, Inc.	2	$4,313
Boehringer Ingelheim International GmbH	11	$4,000
Hoffmann-la Roche Limited	1	$3,300
Blueprint Medicines Corporation	1	$1,120
AstraZeneca	1	$685
Genentech, Inc.	1	$87
Covidien LP	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,282 in reported general payments places this provider in the 85th percentile of 96 medical oncology providers in Colorado.

See all medical oncology providers in Colorado →

Other medical oncology in Aurora

David CamidgeAurora$648K
Paul BunnAurora$354K
Sapna PatelAurora$186K
Sunnie KimAurora$81K
Virginia BorgesAurora$68K
Erin SchenkAurora$63K
Karl LewisAurora$62K
Jose PachecoAurora$50K
Leonard GlodeAurora$49K
Christopher LieuAurora$28K

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →